{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:19:16Z","timestamp":1772119156893,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Democritus University of Thrace"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\u00a0This report describes the first successful administration of ravulizumab, a C5 complement inhibitor, in the treatment of life-threatening intravascular hemolysis (IVH) caused by delayed hemolytic transfusion reaction (DHTR) in a 22-year-old woman. The patient developed acute IVH with severe anemia and hemodynamic instability seven days after receiving a blood transfusion for posthemorrhagic anemia following a missed abortion. Laboratory investigations revealed anti-e and anti-Jka alloantibodies consistent with DHTR. Despite treatment, her hemoglobin level declined further, raising concerns for hyperhemolytic syndrome. After the administration of ravulizumab, her condition improved rapidly, and she was discharged with stable hemoglobin levels. Within three weeks there was full hematologic and biochemical recovery. This case demonstrates the therapeutic potential of ravulizumab in the management of severe complement-mediated hemolysis due to DHTR, and highlights the need for further research on complement inhibitors in similar conditions.<\/jats:p>","DOI":"10.1007\/s00277-025-06585-7","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:46:00Z","timestamp":1756370760000},"page":"4849-4854","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ravulizumab stabilizes life-threating intravascular hemolysis following delayed hemolytic transfusion reaction due to alloantibodies anti-e and anti-Jka: the first successful administration"],"prefix":"10.1007","volume":"104","author":[{"given":"Zoe","family":"Bezirgiannidou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iliana","family":"Stamatiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodoros M.","family":"Theodoridis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eftychia","family":"Kontekaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanouil","family":"Panagiotopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Misidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Vrachiolias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bouse","family":"Malkots","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menelaos","family":"Papoutselis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Kotsianidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanouil","family":"Spanoudakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Liapis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"issue":"5","key":"6585_CR1","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000154811","volume":"35","author":"E Strobel","year":"2008","unstructured":"Strobel E (2008) Hemolytic transfusion reactions. Transfus Med Hemother 35(5):346\u2013353. https:\/\/doi.org\/10.1159\/000154811","journal-title":"Transfus Med Hemother"},{"key":"6585_CR2","doi-asserted-by":"publisher","first-page":"e313","DOI":"10.1016\/j.lpm.2016.06.024","volume":"45","author":"A Brand","year":"2016","unstructured":"Brand A (2016) Immunological complications of blood transfusions. Presse Med 45:e313. https:\/\/doi.org\/10.1016\/j.lpm.2016.06.024","journal-title":"Presse Med"},{"key":"6585_CR3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/9780470986868.ch11","volume-title":"Mollison\u2019s blood transfusion in clinical medicine","author":"HG Klein","year":"2005","unstructured":"Klein HG, Anstee DJ (2005) Haemolytic transfusion reactions. In: Mollison PL, Engelfriet CP, Contreras M (eds) Mollison\u2019s blood transfusion in clinical medicine, 11th edn. Blackwell Publishing, Oxford, pp 455\u2013496","edition":"11"},{"issue":"5\u20136","key":"6585_CR4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/03630269.2018.1540353","volume":"42","author":"E Vlachaki","year":"2018","unstructured":"Vlachaki E, Gavriilaki E, Kafantari K, Adamidou D, Tsitsikas D, Chasapopoulou E, Anagnostopoulos A, Tsapas A (2018) Successful outcome of hyperhemolysis in sickle cell disease following multiple lines of treatment: the role of complement Inhibition. Hemoglobin 42(5\u20136):339\u2013341. https:\/\/doi.org\/10.1080\/03630269.2018.1540353","journal-title":"Hemoglobin"},{"key":"6585_CR5","doi-asserted-by":"publisher","unstructured":"Mpinganzima C, Haaland A, Holm AGV, Thein SL, Tj\u00f8nnfjord GE, Iversen PO (2020) Two consecutive episodes of severe delayed hemolytic transfusion reaction in a sickle cell disease patient. Case Rep Hematol. 2020:2765012. https:\/\/doi.org\/10.1155\/2020\/2765012","DOI":"10.1155\/2020\/2765012"},{"issue":"8","key":"6585_CR6","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1182\/blood-2015-09-669770","volume":"127","author":"G Dumas","year":"2016","unstructured":"Dumas G, Habibi A, Onimus T, Merle JC, Razazi K, Dessap AM, Galact\u00e9ros F, Michel M, Fr\u00e9meaux-Bacchi V, Noizat-Pirenne F, Bartolucci P (2016) Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients. Blood 127(8):1062\u20131064. https:\/\/doi.org\/10.1182\/blood-2015-09-669770","journal-title":"Blood"},{"key":"6585_CR7","doi-asserted-by":"publisher","first-page":"e931107","DOI":"10.12659\/AJCR.931107","volume":"22","author":"G Cannas","year":"2021","unstructured":"Cannas G, Dubreuil L, Fichez A, Gerfaud-Valentin M, Debard AL, Hot A (2021) Delayed severe hemolytic transfusion reaction during pregnancy in a woman with \u03b2-thalassemia intermedia: successful outcome after Eculizumab administration. Am J Case Rep 22:e931107. https:\/\/doi.org\/10.12659\/AJCR.931107","journal-title":"Am J Case Rep"},{"issue":"10","key":"6585_CR8","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1111\/trf.17995","volume":"64","author":"BD Adkins","year":"2024","unstructured":"Adkins BD, Kaylani SZ, Nero A, Ibrahim IF, Shen YM, Sarode R (2024) How do we manage hyperhemolysis syndrome. Transfusion 64(10):1822\u20131829. https:\/\/doi.org\/10.1111\/trf.17995","journal-title":"Transfusion"},{"issue":"12","key":"6585_CR9","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1111\/j.1537-2995.2005.00608.x","volume":"45","author":"K Darabi","year":"2005","unstructured":"Darabi K, Dzik S (2005) Hyperhemolysis syndrome in anemia of chronic disease. Transfusion 45(12):1930\u20131933. https:\/\/doi.org\/10.1111\/j.1537-2995.2005.00608.x","journal-title":"Transfusion"},{"key":"6585_CR10","doi-asserted-by":"publisher","unstructured":"Eberly LA, Osman D, Collins NP (2015) Hyperhemolysis syndrome without underlying hematologic disease. Case Rep Hematol. 180526. https:\/\/doi.org\/10.1155\/2015\/180526","DOI":"10.1155\/2015\/180526"},{"issue":"4\u20135","key":"6585_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/17474086.2024.2348662","volume":"17","author":"P Evangelidis","year":"2024","unstructured":"Evangelidis P, Evangelidis N, Vlachaki E, Gavriilaki E (2024) What is the role of complement in bystander hemolysis? Old concept, new insights. Expert Rev Hematol 17(4\u20135):107\u2013116. https:\/\/doi.org\/10.1080\/17474086.2024.2348662","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"6585_CR12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2450\/2007.0047-07","volume":"5","author":"R Reverberi","year":"2007","unstructured":"Reverberi R, Reverberi L (2007) Factors affecting the antigen-antibody reaction. Blood Transfus 5(4):227\u2013240. https:\/\/doi.org\/10.2450\/2007.0047-07","journal-title":"Blood Transfus"},{"issue":"2","key":"6585_CR13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1182\/bloodadvances.2019001143","volume":"4","author":"ST Chou","year":"2020","unstructured":"Chou ST, Alsawas M, Fasano RM, Field JJ, Hendrickson JE, Howard J, Kameka M, Kwiatkowski JL, Pirenne F, Shi PA, Stowell SR, Thein SL, Westhoff CM, Wong TE, Akl EA (2020) American society of hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv 4(2):327\u2013355. https:\/\/doi.org\/10.1182\/bloodadvances.2019001143","journal-title":"Blood Adv"},{"key":"6585_CR14","doi-asserted-by":"publisher","first-page":"e31061","DOI":"10.1002\/pbc.31061","volume":"71","author":"A Lapite","year":"2024","unstructured":"Lapite A, Bhar S, Fasipe T (2024) Eculizumab for management of hyperhemolysis syndrome in pediatric patients with sickle cell disease: a single-center case series. Pediatr Blood Cancer 71:e31061. https:\/\/doi.org\/10.1002\/pbc.31061","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"6585_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.6004\/jadpro.2024.15.6.4","volume":"15","author":"M Reid","year":"2024","unstructured":"Reid M, Fedutes Henderson BA (2024) Sutimlimab for cold agglutinin disease. J Adv Pract Oncol 15(6):389\u2013395. https:\/\/doi.org\/10.6004\/jadpro.2024.15.6.4","journal-title":"J Adv Pract Oncol"},{"issue":"5","key":"6585_CR16","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1111\/trf.15227","volume":"59","author":"CL Dean","year":"2019","unstructured":"Dean CL, Maier CL, Chonat S, Chang A, Carden MA, El Rassi F, McLemore ML, Stowell SR, Fasano RM (2019) Challenges in the treatment and prevention of delayed hemolytic transfusion reactions with hyperhemolysis in sickle cell disease patients. Transfusion 59(5):1698\u20131705. https:\/\/doi.org\/10.1111\/trf.15227","journal-title":"Transfusion"},{"issue":"6","key":"6585_CR17","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","volume":"133","author":"JW Lee","year":"2019","unstructured":"Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, Pessoa V, Gualandro S, F\u00fcreder W, Ptushkin V, Rottinghaus ST, Volles L, Shafner L, Aguzzi R, Pradhan R, Schrezenmeier H, Hill A (2019) Ravulizumab (ALXN1210) vs Eculizumab in adult patients with PNH Naive to complement inhibitors: the 301 study. Blood 133(6):530\u2013539. https:\/\/doi.org\/10.1182\/blood-2018-09-876136","journal-title":"Blood"},{"issue":"6","key":"6585_CR18","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","volume":"133","author":"AG Kulasekararaj","year":"2019","unstructured":"Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R, Gonzalez-Fernandez FA, Gaya A, Lee JW, Gutierrez EO, Piatek CI, Szer J, Risitano A, Nakao S, Bachman E, Shafner L, Damokosh AI, Ortiz S, R\u00f6th A, de Peffault R (2019) Ravulizumab (ALXN1210) vs Eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood 133(6):540\u2013549. https:\/\/doi.org\/10.1182\/blood-2018-09-876805","journal-title":"Blood"},{"key":"6585_CR19","doi-asserted-by":"publisher","first-page":"100855","DOI":"10.1016\/j.xkme.2024.100855","volume":"6","author":"BP Dixon","year":"2024","unstructured":"Dixon BP, Kavanagh D, Aris ADM, Adams B, Kang HG, Wang E, Garlo K, Ogawa M, Amancha P, Chakravarty S, Heyne N, Kim SH, Cataland S, Yoon SS, Miyakawa Y, Luque Y, Muff-Luett M, Tanaka K, Greenbaum LA (2024) Ravulizumab in atypical hemolytic uremic syndrome: an analysis of 2-year efficacy and safety outcomes in 2 phase 3 trials. Kidney Med 6:100855. https:\/\/doi.org\/10.1016\/j.xkme.2024.100855","journal-title":"Kidney Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06585-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06585-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06585-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:30:42Z","timestamp":1761283842000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06585-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["6585"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06585-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5735391\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"30 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The patient has provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"The use of ravulizumab in this case was approved by the Ethics Committee of the Hospital (Protocol: No. 4\/31\/795).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethical approval"}},{"value":"All authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}